Standard Approach to atMP tissue colLEction (SAMPLE)

“**先进治疗药物产品(ATMPs)** **是新一代的治疗方法，它使用患者的细胞作为“药物”来治疗各种疾病。**虽然已经报道了令人鼓舞的结果，但这项技术复杂、昂贵，目前只有少数患者可以使用。在**2018** ** ** ** *英国** ** *形成了**由**细胞和基因治疗弹射器**支持的**三个先进治疗中心(attc)**网络。atc网络的合作伙伴包括：ATMP开发商和制造商、国家血液服务中心、医院、大学、物流供应商、原材料供应商和技术提供商。该项目由iMATCH ATTC（创新曼彻斯特高级治疗中心中心）领导，但涉及与其他两个ATTC（中部和威尔士ATTC和北方联盟ATTC）的合作，并引入了一个新的合作伙伴（伦敦盖伊和圣托马斯医院），以扩大ATTC以外的活动。该**项目**"" **SAMPLE**“”将利用一组具有更有效合作愿景的合作者，以便我们能够开发一种标准化的方法来收集组织和细胞为基础的起始材料，这些材料对于制造先进治疗药物产品至关重要。最终，做出改进，为患有癌症和非癌症疾病的儿童和成人提供更多改变生活的治疗方法。该项目联合了来自苏格兰、英格兰和威尔士的专家：NHS血液与移植、SNBTS、克里斯蒂NHS基金会信托、曼彻斯特大学NHS基金会信托、纽卡斯尔泰恩河畔医院NHS基金会信托和4家在提供先进疗法的不同方面具有特定专业知识的企业。4个商业伙伴是；渐进线、Autolus、Cellular Therapeutics和TrakCel以及3家来自全球药品制造商和技术提供商的非资助参与：诺华、吉利德和Terumo BCT。我们将重点关注：协调患者细胞收集，处理和储存这些细胞，并使有效的系统能够从患者或供体中收集样本，从而简化生产流程并使接受治疗的患者数量增加。英国在这些类型的治疗方面处于世界领先地位，Innovate UK的这项投资将建立在这些创新疗法和技术的基础上，从而改善英国人口的生活，同时也使英国成为投资的目的地，以及其他非英国开发的治疗方法的试验和最终的标准治疗。”

"**Advance Therapy Medicinal Products (ATMPs)** **are a new generation of treatments which use patients' cells as 'drugs' to treat a variety of diseases.** Although encouraging results have been reported, this technology is complex, expensive and currently only available to small numbers of patients.In **2018** the **UK** have formed **a network of three Advanced Therapy Treatment Centres (ATTCs)** supported by the **Cell & Gene Therapy Catapult**. The ATTC network have partners made up of: ATMP developers & manufacturers, National Blood Services, Hospitals, Universities, logistics providers, raw materials suppliers & technology providers. This project is being led by the **iMATCH ATTC** (innovate Manchester Advanced Therapy Centre Hub) but involves collaboration with the other 2 ATTCs Midlands & Wales ATTC and Northern Alliance ATTC and introduces a new partner (Guy's & St Thomas's Hospital, London) to expand activities outside the ATTCs. This **Project** ""**SAMPLE**"" will harnesses a group of collaborators who share a vision of working more efficiently together so we can develop a standardised approach to the collection of tissue & cell based starting materials essential to the manufacture of Advanced Therapy Medicinal Products. Ultimately, making improvements enabling more life changing treatments to be provided to children and adults with cancer and non-cancer diseases.This project unites experts from Scotland, England & Wales: NHS Blood & Transplant, SNBTS, The Christie NHS Foundation Trust, Manchester University NHS Foundation Trust, The Newcastle upon Tyne Hospitals NHS Foundation Trust and 4 businesses with specific expertise in different aspects of delivering Advanced Therapies. The 4 commercial partners are; Asymptote, Autolus, Cellular Therapeutics & TrakCel as well as 3 non-funded participation from global medicine manufacturers and technology providers: Novartis, Gilead & Terumo BCT.We are going to focus on: coordinating patient cell collection, processing and storage of those cells and enabling efficient systems to collect **SAMPLES** from the patient or donor and so streamlining the manufacture and enabling an increase in the number of patients being treated.The UK is a world leader in these types of treatments and this investment by Innovate UK will build on these innovative therapies and technologies thereby improving the lives of the UK population but also making the UK a destination for both investment and also other non-UK developed therapies in both trials and ultimately standard therapies."